Metsera, Inc.'s Quiet Period Will End on March 12th (NASDAQ:MTSR)

Metsera's (NASDAQ:MTSR - Get Free Report) quiet period will expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analysts Set New Price Targets

Several brokerages recently weighed in on MTSR. Bank of America began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target for the company. Guggenheim began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $56.00 price target for the company. Cantor Fitzgerald began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating for the company. Finally, Evercore ISI began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating for the company.

Metsera Stock Performance

MTSR stock traded down $1.45 on Friday, hitting $25.47. The company had a trading volume of 495,468 shares, compared to its average volume of 588,274. Metsera has a 12-month low of $24.19 and a 12-month high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.